China's economy slows to 4.3% annual pace of growth in April-June
Source link
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
BI 3034701 is a potential first-in-class triple agonist designed to activate the GLP‑1, GIP, and NPY2 receptors.1 By engaging these three complementary biological pathways, the molecule aims to address obesity…







